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Abstract
The cost of conducting multi-site clinical trials has significantly increased over time, with site
monitoring, data management, and amendments being key drivers. Clinical trial data manage-
ment approaches typically rely on a central database, and require manual efforts to encode and
maintain data capture and reporting requirements. To reduce the administrative burden, time,
and effort of ensuring data integrity and privacy in multi-site trials, we propose a novel data
management framework based on permissioned blockchain technology. We demonstrate how our
framework, which uses smart contracts and private channels, enables confidential data commu-
nication, protocol enforcement, and and an automated audit trail. We compare this framework
with the traditional data management approach and evaluate its effectiveness in satisfying the
major requirements of multi-site clinical trials. We show that our framework ensures enforcement
of IRB-related regulatory requirements across multiple sites and stakeholders.
1 INTRODUCTION
The cost of conducting multi-site research has significantly increased over time, with $43 billion spent in
the US in 20131,2. A significant portion of this cost was incurred by site monitoring, data management,
and verification. Typically, a clinical trial involves two phases of amendments to the protocol, each
requiring $450,000. As multi-site trials are expanding to multiple sites to recruit and collect data
from more individuals across a diverse population, initiation of such studies experiences a delay due
to the sites’ reliance on its own institutional review board (IRB) for ethical reviews. To expedite
the review process and reduce the administrative burden, time, and cost of redundant reviews, the
National Institutes of Health (NIH) issued a policy requiring a single IRB (sIRB) in NIH-funded
multi-site clinical research studies3. Participating sites will still be responsible for obtaining informed
consent from subjects prior to enrollment, implementing the approved protocol, and reporting cases of
adverse events. Data verification may happen in real time as it is collected, but often occurs through
Extract-Transfer-Loads, where problems with data integrity from a site are not detected until later.
Moreover, once a study protocol is approved, it is difficult to track the activities of participating sites
and ensure that they adhere to the required guidelines.
In this context, it is more relevant than ever to design a secure, efficient, and robust infrastruc-
ture that not only enforces the regulatory obligations in a multi-site clinical research study, but also
ensures an elevated level of data security and optimization of cost. To address the above-mentioned
challenges, we propose the design of a novel data management framework based on blockchain technol-
ogy, smart contracts, and private channels. Blockchain, particularly private blockchain framework, has
been proven to be a promising solution for several applications in medical and healthcare research4–6.
Although the authors in7 proposed a public, cryptocurrency-based blockchain for clinical research, it
does not provide a practical solution to meet regulatory obligations, where only known parties are
allowed to submit study data. Further, in a use case comprising interested stakeholders, the need for
cryptocurrencies as incentives is extraneous. Recent literature on auto-generation of smart contracts
from clinical trial protocols re-instates the value of blockchain and smart contracts in enforcing protocol
guidelines8,9.
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In this paper, we present a novel, decentralized data management framework based on a private
blockchain with private channels to improve data privacy, data integrity, and traceability. We demon-
strate how to build a blockchain network comprising different personnel in a multi-site study, create
private channels for segregating sensitive data, and leverage smart contracts for enforcing the require-
ments of a study protocol. We evaluate the effectiveness of our proposed framework in satisfying the
major requirements of NIH-funded multi-site clinical trials10–13: eligibility criteria for subject enroll-
ment, protection of sensitive data, provenance of data collected from multiple sites, tracking and con-
ducting schedule of activities, timely reporting of adverse events, ensuring valid protocol amendments,
audit trail, and assisting in meta-analysis. We compare and contrast our method with the centralized
trial management approach. Finally, to provide a holistic overview of implementing blockchain-based
solutions for biomedical and healthcare applications, we discuss the challenges entailed by it.
BACKGROUND
1.1 Traditional data management framework for a multi-site clinical trial
In a multi-site clinical trial, the trial protocol must be followed by participating clinics spanning across
multiple clinical center networks. Researchers conducting the trial at multiple sites maintain a single
database to store all the data related to the trial. Typically, PIs and other clinic staff use a web-
based application to access trial information, training material, and upload collected data to a central
database, which is located at the coordinating center.
In a traditional clinical trial data management system, when a subject is enrolled, a unique iden-
tification number is generated and appended to the corresponding entry on the database. A schedule
of activities for each visit is generated by the PI. The web application has a tracking and notification
system which can advise clinic staff on subject follow-up windows and required laboratory activities.
Tracking a subject begins at screening and continues throughout the trial. During each visit, data is
collected in the form of questionnaires, samples, and lab results. The participating clinic sites use the
web application to update data from paper-based forms and questionnaires. The data entry system is
designed to mirror the forms for accuracy of data entry. This is linked to a relational database that
is managed by the coordinating center at a central location. Such a framework is prone to the risk of
single point of failure (SPOF) and can result in the loss of data.
Following a subject visit, the clinic coordinator reviews the required forms and laboratory reports
for accuracy and completeness. If the data entered by the clinic staff is overridden, it is flagged for
review by the coordinator. The database can also be accessed by the Data and Safety Monitoring Board
(DSMB), who review the trial and cases of serious adverse events (SAE) to provide recommendations
for continuation of the trial and clinical performance. To assist with trial monitoring and quality
control, data edit reports, including site assessments, are generated. The system requires nightly
backups and storage of backup tapes in a locked, fire-proof and water-proof area at multiple locations
for data recovery, in case of a disaster. Such manual intervention for data management and maintenance
increases the cost of trial and the risk of error. Moreover, the data recovery time for such a system
is high, which impacts the trial. Figure 1 illustrates the traditional centralized data management
framework used in multi-site clinical trials.
1.2 Blockchain technology
Blockchain technology has been perceived to revolutionize several domains, including finance14,15,
healthcare4,5, 16, supply chain17, and the government sector18–20. Blockchain is a decentralized ledger
capable of maintaining an immutable record of transactions and tracking assets. The ledger has a
verified proof of transactions in blocks that are linked together to form a chain. Each block con-
tains a hash, a list of valid transactions, and a hash of the previous block, attributing to making
the blockchain tamper-proof. Although Bitcoin14 was the first cryptocurrency-based implementation
of blockchain, many blockchain frameworks with varying features have been introduced over the last
decade. Based on the underlying network, blockchains can be categorized into permissionless and
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Figure 1: Traditional centralized system of data management and communication in a multi-site clinical
trial. Data collected from enrolled subjects at each site is stored in a centralized database maintained
by the coordinating center. The database is accessible to the IRB, DSMB, sponsors, and regulatory
agency. The de-identified data is converted into SAS format prior to secondary sharing for analysis.
permissioned frameworks. A permissionless blockchain supports anonymous participants to join the
network and participate in consensus without any prior approval. They are usually driven by the
Proof of Work (PoW) protocol to achieve consensus. Bitcoin and many other cryptocurrency-based
implementations are based on such permissionless or public network. Contrary to this, in a permis-
sioned blockchain, only an interested stakeholder with a unique private identity can join the network,
read the ledger, propose transactions, and participate in consensus. The transactions can be veri-
fied through different consensus mechanisms, such as Proof of Elapsed Time (PoET)21 and Practical
Byzantine Fault Tolerance (PBFT)22. A majority of permissioned blockchains support smart contracts
that define a set of rules to govern transactions within the network. Smart contracts are computer
programs that can implement functionalities to enforce rules defined in a business agreement and be
executed automatically as part of invoked transactions. They can further enforce authorized data
sharing through fine-grained access control6.
1.3 Private blockchains for healthcare applications
Private blockchain is fundamental in most industry use cases, such as finance, insurance, supply chain,
and healthcare. A majority of biomedical and healthcare applications involve interested stakeholders
as participants, for which blockchain frameworks built on a private network are more suitable. They
do not require incentives, in the form of cryptocurrencies, for participation. Some of the more popular
private blockchain implementations include Hyperledger23, Ethereum24, and R3 Corda25.
In healthcare applications, a private blockchain can be used for secure data collection, management,
and sharing. For instance, MedRec5, a decentralized data management system based on Ethereum’s
private network, can share electronic medical records between patients and providers. The authors
in26 used Ethereum for secure analysis and management of medical sensors. The Orange Consent
Management System6, built on Hyperledger Fabric, provides a consent management system for users to
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share their health data. In the article4, the authors used Hyperledger Fabric to develop a decentralized
framework for consent management and secondary use of research data. They also demonstrated how
to leverage smart contracts to enforce IRB regulations in a research study.
1.4 Hyperledger Fabric
Hyperledger Fabric is a private blockchain framework developed by The Linux Foundation. It offers
a modular architecture supporting pluggable components, such as consensus protocol, encryption,
identity management, and membership services. The private network comprises multiple nodes, a
smart contract or chaincode, and a ledger containing a state database and a log of transactions. A
node can be maintained by an individual or multiple users. Based on their functionalities, the nodes
can be categorized into client (invokes transactions), peer (maintains and updates ledger), and orderer
(supports communication and maintains order of transactions). This is illustrated in Figure 2.
• Client node: It submits transaction-invocation to the endorsers and transaction-proposals to the
orderer. It is connected to both peer and orderer nodes.
• Peer node: It commits transactions and maintains the world state of the ledger. It updates the
ledger after receiving ordered states from the orderer. A peer node can act as an endorser to
sign a proposed transaction before it is sent to the orderer.
• Orderer node: It runs a broadcast communication service to guarantee delivery. It delivers
transactions to the peer nodes after verifying the endorsement message.
A smart contract, also known as chaincode in Hyperledger Fabric, is a self-executing logic that
represents agreements or a set of rules which govern transactions in a blockchain network. The rules
are implemented as functions in chaincode. All data transactions that require accessing the ledger
invoke corresponding chaincode functions. Hyperledger Fabric implements endorsement policies or
conditions to validate proposed transactions. Once a transaction is proposed by a client, it must be
endorsed by the pre-defined endorsing nodes. The endorsement signatures are collected and sent to
the orderer. The orderer verifies the endorsement message, such as valid number of endorser signatures
and simulated transaction results, from all endorsers. The collected transactions are then sent as a
new block to all peers. A trusted Membership Service Provider (MSP) enrolls the participants in the
network. MSP provides a verifiable digital identity to all entities in the blockchain network, such as
peers, orderers, and clients. It serves as a trusted authority which abstracts the process of issuing
cryptographic certificates and user authentication. Some of the other notable features of Hyperledger
Fabric include:
• Confidentiality: In addition to a private network, it allows creation of private channels comprising
a sub-group of network participants. All information related to a channel are accessible only to
the members of that channel, thereby elevating the level of confidentiality.
• Cryptographic identity management: A membership identity service manages user IDs and au-
thenticates all participants on the network. Additional access control can be implemented for
specific network operations.
• Modular design: It supports a modular architecture that allows different components, such as
membership function and consensus, to be plug-and-play.
2 METHODS
To address the challenges experienced by a traditional data management system in multi-site clinical
trials, we design a blockchain-based infrastructure for collecting, storing, managing, and sharing trial
data. We model our system on Hyperledger Fabric to leverage its inherent features, such as private
network, private channels, and smart contract. In this section, we describe the design of our pro-
posed system: setting up the network, installing private channels, and writing channel-specific smart
contracts.
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Figure 2: System architecture of Hyperledger Fabric. The private network consists of peer nodes (also
acting as client and endorser nodes) and an orderer node. Peer nodes 1 and 3 belong to one channel
(shown in red), maintains a ledger, and operates on the same smart contract, whereas peer node 2
belong to a different channel (shown in blue) and has a different ledger and smart contract. The orderer
node maintains the order of proposed transactions, validates endorsement signatures, and broadcasts
messages to peers.
2.1 Setting Up a Blockchain Network
Prior to setting up a blockchain network, it is important to identify the stakeholders or participants
and their roles. Based on a comprehensive study of NIH-funded multi-site clinical trial protocols10–13,
we enlist the following personnel to be most important in conducting a multi-site clinical trial:
• Subject - An individual about whom an investigator collects data to conduct a research study.
Data can be collected through intervention or interaction with the individual.
• Principal Investigator (PI) - The primary individual responsible for preparing, conducting, and
administering the study at each site of a multi-site clinical trial. While maintaining the ethical
conduct and supervision of a study, PIs must protect the rights, safety, and welfare of subjects
enrolled in the trial. They have access to the data and specimen collected from subjects, results
of analysis, cases of adverse events, and study reports.
• Coordinating Center (CC) - A center that is responsible for coordinating a multi-site clinical
trial. They generate data edit reports, schedule of activities for subjects, and communicate them
to appropriate stakeholders. They maintain a central database that also stores SAS data.
• Data Safety and Monitoring Board (DSMB) - An independent group of experts that periodically
review and evaluate the accumulated study data for participant safety and study progress, make
recommendations concerning the continuation, modification, or termination of the trial.
• Institutional Review Board (IRB) - A board designated to protect the rights, safety, and wellbeing
of human subjects participating in a clinical trial. They review all aspects of a trial, including
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approval of study material before and during the study. The new policy of NIH requires a single
IRB (sIRB) for conducting ethical review of multi-site studies.
• Regulatory agencies - Regulatory agencies, such as The Food and Drug Administration (FDA),
ensure medical treatments are safe and effective for subjects to use. They perform inspections of
study sites to protect the rights of subjects and to verify the quality and integrity of the data.
• Sponsors - An individual, institution, or organization that initiate, manage, and fund a clinical
trial, but does not actually conduct it.
• Analysts - Researchers or statisticians who gather, review, and organize trial results, including
de-identified data collected from subjects.
We consider each personnel involved in a multi-site clinical trial to be a node in the blockchain
network. A node can represent an individual (PI), an agency (subject agency), or an organization
(sIRB). In a standard blockchain network, each node maintains a single ledger and operates on a
smart contract. The smart contract enforces pre-approved guidelines of the study protocol, including
the method of collecting, storing, and sharing trial data. Raw data can be directly stored on the
ledger. However, for large-scale data, such as wearable sensor readings or genomic data, it is advisable
to store it off-chain with an encrypted key linking it to the ledger.
2.2 Creating Private Channels
Hyperledger Fabric offers an additional level of data privacy by incorporating private channels between
subset of members in the network. A network supports multiple channels, each maintaining a separate
smart contract and a ledger. It ensures confidentiality by making all data, including transactions,
ledger, members, and channel information invisible and inaccessible to any member not explicitly
granted access to that channel. These light-weight channels further reduce the storage space and
energy consumption required to maintain a blockchain network. Multiple channels improve transaction
throughput by allowing transactions to be executed in parallel27. For a multi-site clinical trial, we
incorporate private channels to streamline data flow and limit data access to designated personnel.
We partition the network into the following private channels:
2.2.1 Subject Enrollment Channel
Once subjects are deemed eligible for participation in a clinical trial, PIs collect their data, including
consent and protected health information (PHI), for enrollment. This channel corresponds to the
consent management system in a clinical trial. To ensure only intended members in the blockchain
network have access to such sensitive data, we create a private channel for managing enrollment-specific
information. It involves PIs, subjects, coordinating center, and DSMB. This is denoted by the blue
channel in Figure 3.
2.2.2 Trial Monitoring Channel
As subjects consent to participate in the study, raw data or samples are collected from them at regular
intervals by the trial sites or clinics. We create a separate channel, involving PIs, DSMB, sponsors,
coordinating center, and regulatory agencies, for monitoring the activities conducted in a trial. The
members of this channel have access to the study data gathered from subjects, activities conducted on
each visit, test results, and cases of adverse events experienced during the trial. This is shown by the
green channel in Figure 3.
2.2.3 Data Analysis Channel
The analysts conduct analyses on de-identified data to get an insight into the effectiveness of the
study. We create a data analysis channel between PIs and analysts to enable secondary sharing of
de-identified data for analysis. The yellow channel in Figure 3 depicts this.
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Figure 3: A blockchain-based system with private channels for managing data in a multi-site clinical
trial. Each participant maintains a ledger and operates on a smart contract of its member channel. It
maintains confidentiality of information and restricts access to channel further restrict unauthorized
data access by limiting data transactions to channel members.
2.2.4 Study Report Channel
A clinical study report is a detailed document describing the methods and results of a trial. It integrates
clinical and statistical description, presentations, and analyses results. A private channel, comprising
PIs, sponsors, regulatory agencies, coordinating center, and subjects, will help in managing and sharing
study report documents. This is indicated by the pink channel in Figure 3.
Hence, in this framework, each node maintains a ledger corresponding to each of its member channel,
rather than a single ledger containing the entire trial data. Transactions within each channel is
further governed by its own smart contract. Although our proposed system design is based on
NIH-funded multi-site clinical trial protocols, it can be extended to meet specific requirements of
other studies.
2.3 Implementing Channel-Specific Smart Contracts
Smart contracts are essential in implementing and enforcing the guidelines of a clinical trial protocol4.
These programs can define a list of functionalities incorporating specific requirements for conducting a
clinical trial. Blockchain participants can interact with an application interface to invoke the functions
in the smart contract. For each data transaction request, the corresponding function verifies if it
was proposed by a valid user for a valid channel, data type, and time, thereby allowing fine-grained
access control. Herein, we provide a detailed description of the smart contracts specific to the above-
mentioned private channels.
2.3.1 Smart Contract for Subject Enrollment
Each clinical trial protocol defines a set of inclusion and exclusion criteria that determine if a candidate
is eligible to participate in the study. This often requires verifying the age, gender, pre-conditions, and
past treatment of the candidates. An enrollment function within the smart contract can check for a set
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of constraints prior to enrolling candidates and adding their data to the ledger. Since PIs are respon-
sible for de-identification of data, they can trigger a smart contract functionality that will disassociate
clinical information from a subject’s identifiable information. While enrolling, all the sensitive infor-
mation collected from the subjects, such as PHI and consent information, can be stored on the ledger.
The smart contract can further check if intended members attempt to invoke specific functions. For
instance, subjects can attempt to read their data stored by the PIs on the ledger. Similarly, members
of DSMB can have read or write access to this ledger. Limiting access of such sensitive information to
designated members in the network further elevates data privacy. Once approved, the subject’s record
will be added to the ledger.
2.3.2 Smart Contract for Trial Monitoring
The trial monitoring channel collects and manages different types of data during the course of the
trial. In a multi-site research study, each clinic conducts a given set of activities based on a schedule
of activities defined in the protocol. This may include collecting questionnaire or samples from sub-
jects, running laboratory tests, and reporting cases of adverse events. A smart contract specific to
this channel can verify if the data corresponding to scheduled activities was entered into the system
during an approved timeline. It can further check if specific pre-requirements were met prior to data
entry. Since current clinical trial management systems often experience difficulty in reporting cases of
adverse events or laboratory abnormalities in a timely manner, smart contracts can be leveraged to
record, track, and update such events in real-time. In addition to expedited intervention, it provides
a transparent and reliable event monitoring approach for the regulatory agency. Moreover, in the case
of any discrepancy or attempts to tamper with the recorded data, the smart contract will flag the
transaction, which is recorded in the immutable transaction log. In a multi-site trial, this framework
ensures provenance and quality of data collected from different sites. The implementation of a single
smart contract across all sites further guarantees compliance with IRB-approved study protocol and
consistent data framework.
2.3.3 Smart Contract for Data Analysis
The de-identified data collected from subjects are shared with analysts for secondary data analysis.
The above-mentioned consent management system coupled with smart contract limit unauthorized
data access, even for the least restrictive blanket consent. The smart contract checks the consent
information stored on the ledger to ensure the validity of the request. Once approved, de-identified data
in SAS format is shared with them. Secondary research includes topics like longitudinal data analysis,
subgroup analysis, non-linear relationships, and meta-analysis. Based on its underlying programming
language, a smart contract can further invoke modules or functionalities that automatically execute
the analysis code.
2.3.4 Smart Contract for Study Report
A clinical study report is an integrated report containing clinical and statistical description, presenta-
tions, and analyses. It also includes sample case report forms, information related to the investigatory
products, technical statistical documentation, patient data listings, and technical statistical details
such as derivations, computations, analyses, and computer output28. The smart contract designed for
this channel accesses the transaction log to automatically generate audits for evaluating participating
sites’ performance, protocol adherence, and efficacy of the trial. This can significantly reduce the
burden of manual audit and incidents of selective-reporting, under-reporting, or mis-reporting. This is
also applicable to periodic generation of reports for continuous reviews. This improves the credibility
and integrity of the study report submitted to the regulatory authority.
Protocol amendments occur frequently in clinical trials, with an average of 2.3 amendments per
trial29. When amendments are unavoidable, it is important to execute and track the amendments
across all participating sites and stakeholders. Implementing such amendments in our proposed
framework would require updating the channel-specific smart contracts such that all intended
8
stakeholders are aware of and comply with the update. This is achieved by a specialized higher level
system chaincode, that incorporates and tracks updates made to the channel-specific chaincodes. For
transparency, prior to initiating an update for a smart contract, an endorsement policy is designed to
validate it.
3 EVALUATION
We evaluate the effectiveness of our proposed data management system in enforcing the major require-
ments of NIH-funded multi-site clinical trials.
1. Audit Trail: As noted by the National Institute of Drug Abuse (NIDA) in its guide to conduct-
ing high quality research in the Clinical Trials Network (CTN), proper documentation of how
study procedures are implemented is necessary at all times30. Maintaining audit trail involves
regularly monitoring study sites, verifying study compliance, and reporting on monitoring visits.
Since current systems rely on manual effort to record and maintain documentation, they experi-
ence a delay during staff turnover or unplanned emergencies. Blockchain maintains an immutable
log of data transactions and recorded activities, hence eliminating the need for paper-based trails.
Any attempts to tamper with the cryptographically secure transactions are automatically flagged
and reported. This strict standard for study oversight improves traceability and fidelity of the
research.
2. Data Privacy: Contrary to a traditional system, a private blockchain framework with private
channels offers elevated data privacy. As discussed in4, blockchain and smart contracts enable
secure consent management and secondary data sharing. PIs can use the system to anonymize
data, store sensitive information on the ledger and de-identified data on a database using en-
crypted keys. Based on the consent information saved on the ledger, third-party researchers
access the de-identified data using one-time encryption keys. This restricts them from access-
ing the data if permissions are revoked. Smart contracts further limit unauthorized data usage
through fine-grained access control. Permission for data access can be granted to an individual
for a specific data type and duration. Private channels bolster data privacy without affecting
transaction efficiency. A recent study showed how a multi-channel setup improves transaction
throughput by allowing multiple independent transactions to be executed in parallel27.
3. Data Integrity: Data provenance and integrity ensure the validity of a study and its findings.
Data collection and reporting must follow an approved guideline and standardized representation.
This is particularly relevant in multi-site studies, where raw data, questionnaires, and lab reports
are collected and curated by multiple participating sites and their personnel. A decentralized
system like blockchain expedites data entry, which are time-stamped and nearly impossible to
forge once it resides on the system. This automatically enhances trust in the system even in the
absence of a centralized trusted authority. To enforce data integrity and coherence across all
sites, smart contract functions define and verify a set of criteria that must be met prior to data
entry. It can check if eligibility criteria, such as inclusion and exclusion criteria, are met prior to
data entry, sites followed a schedule of activities on each visit, and data standards like HL7 and
SNOMED CT are followed. This reduces cases of data fraud or inconsistency that are usually
detected later in the trial.
4. Protocol Violation: Protocol violations decrease benefit, increase risk, and affect safety and
welfare of the subjects and integrity of the data31. Once a study protocol is approved, using the
current trial management system, it is difficult to ensure all sites and personnel adhere to it.
A smart contract can verify if certain constraints, as required by the protocol, have been met.
This includes, but is not limited to, inadequate informed consent, subject enrollment criteria,
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and mis-reporting or under-reporting of events, to name a few. Through constraint checks and
automated monitoring, smart contract functions detect and log cases of protocol violation. It
further assists in auto-generating reports to notify regulatory agencies, such as DSMB and IRB,
of such incidents. Correct and timely reporting of protocol violations is essential for the inter-
pretation of results and design of post-approval safety assessments of new interventions32.
5. Protocol Amendment: Amendments to a clinical trial protocol can be challenging for data
analysis and interpretation, specially if they occur part way through the trial33 and can introduce
bias if the changes are made based on the trial data34,35. The implementation and communica-
tion of amendments are also burdensome and potentially costly36. Once a protocol is amended,
all sites must adopt and comply with the updated guidelines. Smart contracts, implementing
protocol guidelines, are updated upon approval from appropriate members, and installed across
all nodes to enforce the updated guidelines and ensure consistency. If an amendment requires
updating a channel-specific smart contract, all the other channels can still operate on their exist-
ing version. Hence, our framework not only provides a transparent approach of version control,
but also a modular design for implementing amendments.
6. Reporting Adverse Events: To fulfill its obligations during the conduct of a clinical study, an
IRB must have information concerning unanticipated problems involving risk to human subjects
in the study, including adverse events that are considered unanticipated problems37. Failure to
report or delayed reporting of an adverse event can have serious consequences on a subject’s
safety and welfare, study results, and validity of the study. Reporting a case of adverse event is
a multi-step process that is often delayed due to manual intervention and lack of a sophisticated
approach of reporting. Smart contract functions, triggered by study coordinators, PIs, or affected
subjects, enable real-time, automated reporting of adverse events to expedite intervention. These
functions can also verify if follow-up studies for assessment were completed. The transaction log
can be accessed to easily track and monitor adverse events. Such an approach enables timely
identification of adverse events and responsiveness to patient safety concerns.
3.1 Comparison
We compare and contrast our proposed blockchain-based system using private channels with the tra-
ditional centralized data management system in Table 1. Since the authors in27 have conducted
comprehensive experiments to benchmark and evaluate the performance of Hyperledger Fabric, we
refer to this work for relevant quantitative evaluations.
Feature Traditional System Blockchain with Private
Channels
Data privacy Data can be accessed by
study personnel with login
credentials
Data access is restricted via en-
cryption, smart contract, and pri-
vate channels
Data storage Data stored at sites and a
central database
Data of a channel is stored on its
member nodes’ ledger
Data recov-
ery
Difficult due to SPOF and
requires daily backups and
redundant storage
Easy recovery from a decentral-
ized network, even if part of it is
down
Cost Low setup cost and high
maintenance cost
High setup cost and low mainte-
nance cost
Table 1: Comparison of a traditional system and our proposed blockchain-based framework for clinical
trial data management.
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4 DISCUSSION
Multi-site clinical trials entail several challenges, including rising cost and lack of a secure, systematic
approach for data management. To address these challenges, we propose a framework based on a per-
missioned blockchain that supports private channels and smart contracts. We partition the network
into multiple channels based on intended data transactions, such as subject enrollment, trial moni-
toring, data analysis, and study report. Each channel comprises designated stakeholders as members
and a smart contract enforcing data transaction guidelines. Building a blockchain network requires
significant technical expertise and a relatively higher initial setup cost. However, it offers significant
advantages over a traditional centralized system. We demonstrate how our solution satisfies the major
requirements of NIH-funded multi-site clinical trials: audit trail, data privacy, data integrity, detecting
protocol violation, protocol amendment, and timely reporting of adverse events.
Although researchers have advocated blockchain technology for healthcare and biomedical appli-
cations, it is still at an early stage of development. Despite the hype revolving around this emerging
technology, one must discern the need for blockchain and the selection of a suitable framework prior
to its adoption38. The translation of IRB-approved guidelines to smart contract functionalities can
be a barrier for the adoption of this technology in clinical trials. To enable seamless transition of
protocol guidelines and reproducibility, our ongoing effort also includes developing a framework that
automatically generates smart contracts from clinical trial protocols. We have applied machine learn-
ing and natural language processing to extract constraints from schedule of activities tables in clinical
trial protocols8. Through a human-in-the-loop visual interface, we verified the semantics extracted
from the tables, such as time of visit, updates to a visit, and activities to be conducted on the visit.
As shown in9, we converted the extracted information to smart contract functionalities using domain-
specific knowledge, represented as ontologies and semantic rules. For future work, we will extend our
blockchain-based trial management system such that regulatory agencies can monitor and retrieve nec-
essary information without the burden of maintaining a node for each clinical trial under surveillance.
Finally, we will investigate different incentive mechanisms for active participation of stakeholders, par-
ticularly in private blockchain frameworks without cryptocurrencies. Currently, we are prototyping
and validating our proposed blockchain-based data management framework for a multi-site drug trial.
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